Thursday, 31 March 2016
Genomic Sequencing Augments Advanced Ingredients to LAMEA Oncology Drug Market
Personalized gene-sequencing popularizes for
narrowed identification of drugs targeted at mutating cancer cells. Immuno-oncology snakes in too.
Contemporary oncology drugs market has extensively evolved over the recent times aided by a series of successful clinical trials. Generalized medicine suffers a setback in this specific segment accounting to dynamic mutation in cancerous cells. Among various therapeutic modalities, chemotherapy has so far been the most commonly practiced, yet shall suffer the same fate. Two basic reasons – experts reaching out non-
toxifying methods and due patent expiration of predominantly popular drugs. In such an environment other modalities, such as immuno- and targeted therapy, rise in demand preference, and hence, market shares.
Trends on trial
We have come a long way with discussions on reducing failure rates of conventional therapies plus eliminating residual toxins left in host bodies. Researchers reap initial success during clinical trials with target-drugs as diverse as the tumor types. Having realized that same
medicines could not be used for similar mutations given the varied structure of host bodies, personal genomics gains importance. Considering individual genetics, experts recommend RNA sequencing for accurate identification of case-specific requirements. Moreover, it holds potential of predictive diagnosis for patients at high risks of oncological complications. Talking about targeting abnormal cells, experts have successfully revised the incurable case of KRAs in lung cancer during primitive research.
Parallel research in fields
of using the human cells against the diseased ones bore fruitful results in recent past. Broadly, immuno- and hormonal therapy exhibit positive signs when brought into mainstream therapeutics. While the prior involves reinjecting modified immune cells into their system to naturally ‘recognize and fight’ cancer cells, the latter consequentially manipulates hormone secretion after interpreting gene expression and detecting anomalies. Relevant compounds show exponential growth in the upcoming decade for oncology drugs market.
LAMEA oncology drugs environment
Challenging the LAMEA market are high costs of advanced treatments that keep
diseased population deprived of relevant services. Government health policies in this regions, thus, have a major play in the oncological drug development and bringing it to these markets. When put up against the healthcare facilities at a global scale, public expectations rise in regard to optimum health services. The rise in incidences of cancer, unfortunately grew at par with the per capita income of the resident population. Among the diverse types, lung cancer and breast cancer registered an all-time high rate of incidence.
Corporate players on the other
hand are aware of the conventional drugs that shall suffer due patent-expiry in recent times. The market prepares itself with increased research and development activities in drug compounds that promise survival through trial procedures in the long run. Besides, incoming throughputs from researchers around the world. It is crucial to realize importance of inter connected development through well collaborated strategies.
Predictions source in from expert analysts for the LAMEA oncology drugs market to grow steadily till 2021. Rise in disposable income of the population in these regions will change the way people opt for anti-cancer therapies.
Demand shall grow for advance therapies, much to experts as well as patient’s relief. Market inclinations have grown strongly for the biological therapeutic drugs, it being the fastest growing segment over the current decade in the region. Considering regional demographics Brazil leads the market in growth.
As estimated in a report published by Allied Market Research “LAMEA Oncology/
Anti-cancer drugs Market - Opportunities and Forecasts, 2014 – 2021”, the market shall experience a stable CAGR of 8.6%. Accordingly, the market size is expected to reach net evaluation of $17,072.2 million by 2021. The report is an extensive analysis of current market structure and its pipeline verticals. It holds quantitative data to support the predicted drivers of market growth, prospective investment pockets and threats posed to the same. Corporate profiling of key regional players gives an insight to prevalent business activities and help stakeholders formulate their strategies.